Skip to Main Content

Paper Details

HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy.
J Immunother Cancer
112
2021
CAR-, CAR-T cells, HLA, HLA Ligand, HLA allotypes, HLA ligand, HLA-I, HLA-I ligands, HLA-I- and, HLA-II, HLA-II ligands, HLA-ligand, Human, PBMCs, T-cell, allergy, autoimmunity, cancer, cell lines, glioblastoma, hla, human, human leucocyte antigen, immune cells, non-canonical genomic regions, peripheral blood mononuclear cells, tumor, tumors
Author NameAffiliation
Roland MartinNeurology Clinic, University Hospital Zurich, University of Zurich
Holger MochUniversity Hospital and University of Zurich
Holger MochUniversity Hospital and University of Zurich
Michael WellerClinical Neuroscience Center and Department of Neurology, University Hospital and University of Zurich
Oliver KohlbacherUniversity of Tubingen
Oliver Kohlbacher
Oliver KohlbacherInstitute for Bioinformatics and Medical Informatics, University of Tubingen
Oliver KohlbacherUniversity of Tubingen
Oliver KohlbacherMax Planck Institute for Developmental Biology
Oliver KohlbacherUniversity of Tubingen
Oliver KohlbacherInstitute for Translational Bioinformatics, University Hospital Tubingen
Oliver KohlbacherUniversity of Tubingen
Oliver Kohlbacher
Oliver KohlbacherInstitute for Bioinformatics and Medical Informatics, University of Tubingen
Oliver KohlbacherUniversity of Tubingen
Oliver KohlbacherMax Planck Institute for Developmental Biology
Oliver KohlbacherUniversity of Tubingen
Oliver KohlbacherInstitute for Translational Bioinformatics, University Hospital Tubingen
  • 1 - 18

Datasets

Release 1.2